Two Sigma Advisers, LP
- SEC CIK
- 0001478735
- Latest filing
- Aug 14, 2026
RARE holding history
Ultragenyx Pharmaceutical Inc. in every 13F filed by Two Sigma Advisers, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RARE overviewAll 13F holders of RAREFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −481,600−100.0% | Sold out | Holders |
| Q4 2025 | 481,600 | $11.1M | <0.1% | −36,100−7.0% | Reduced | Holders |
| Q3 2025 | 517,700 | $15.6M | <0.1% | −342,700−39.8% | Reduced | Holders |
| Q2 2025 | 860,400 | $31.3M | 0.1% | −76,800−8.2% | Reduced | Holders |
| Q1 2025 | 937,200 | $33.9M | 0.1% | +23,700+2.6% | Added | Holders |
| Q4 2024 | 913,500 | $38.4M | 0.1% | −74,300−7.5% | Reduced | Holders |
| Q3 2024 | 987,800 | $54.9M | 0.1% | +545,600+123.4% | Added | Holders |
| Q2 2024 | 442,200 | $18.2M | <0.1% | −6,000−1.3% | Reduced | Holders |
| Q1 2024 | 448,200 | $20.9M | <0.1% | +259,300+137.3% | Added | Holders |
| Q4 2023 | 188,900 | $9.03M | <0.1% | −40,600−17.7% | Reduced | Holders |
| Q3 2023 | 229,500 | $8.18M | <0.1% | −261,000−53.2% | Reduced | Holders |
| Q2 2023 | 490,500 | $22.6M | 0.1% | −7,400−1.5% | Reduced | Holders |
| Q1 2023 | 497,900 | $20.0M | 0.1% | +37,200+8.1% | Added | Holders |
| Q4 2022 | 460,700 | $21.3M | 0.1% | +409,300+796.3% | Added | Holders |
| Q3 2022 | 51,400 | $2.13M | <0.1% | +51,400 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −69,400−100.0% | Sold out | Holders |
| Q3 2021 | 69,400 | $6.26M | <0.1% | −68,500−49.7% | Reduced | Holders |
| Q2 2021 | 137,900 | $13.1M | <0.1% | +5,800+4.4% | Added | Holders |
| Q1 2021 | 132,100 | $15.0M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.